Das tumortherapeutische Potential optimierter Agonisten der Rezeptoren des Apoptose-induzierenden Liganden TRAIL
Loading...
Files
Date
Authors
Publisher
Philipps-Universität Marburg
Abstract
Despite the development of new drugs and the improvement of therapies, the fight against cancer is still ongoing. Apo-2L or tumor necrosis factor (TNF)-related apoptosis ligand, TRAIL, is one of several members of the TNF family and due its selectivity towards transformed versus normal cells it bears the potential as a cancer therapeutic agent. Furthermore, the TRAIL system seems to circumvent the resistance of tumors induced by treatment with chemo- and radiotherapie.
In this study multivalent single chain antibody fragments (scFv fragments) specific for TRAIL-R2 and CD95 were generated and analysed. CDNA was prepared from isolated RNA of hybridoma cells expressing monoclonal antibody for TRAIL-R2 and CD95 (APO-1/Fas) and used for PCR amplification of heavy and light variable regions (VH and VL) genes. The VH and VL expression cassettes were C-terminally fused to a multimerisation domain of a modified leucine-zipper. The recombinant proteins were produced by transformation of E.coli with the generated expression leucine zipper plasmids. Specificity and activity of the in-vitro-refolded scFv-anti-TRAIL-R2 and scFv-anti-APO-1 antibody fragments have been evaluated. The specific binding of the scFv-anti-TRAIL-R2 fragment to TRAIL-R2 expressing tumor cells was confirmed by FACS analysis. Only minimal lytic activity of the scFv-anti-TRAIL-R2 fragment on a variety of tumor cells could be detected. In the case of the scFv-anti-APO-1 fragments, specific binding as well as lytic activity was observed. However, compared to the parental anti-APO-1 antibody the potential of this recombinant antibody was not increased.
In addition, a highly active recombinant version of TRAIL, IZ-TRAIL, was generated in this study. IZ-TRAIL was recombinantly in E.coli expressed and purified in large scale by sequential affinity chromatography. The anti-tumoral efficacy of IZ-TRAIL alone or in combination with different chemotherapeutic drugs was evaluated on a variety of tumor cells. Besides the high apoptosis-inducing activity on cancer cells, no toxicity in mice and on freshly isolated human hepatocytes of either IZ-TRAIL alone or in combination with diverse chemotherapeutic drugs was observed. Therefore, in contrast to non-tagged versions of TRAIL this recombinant IZ-TRAIL shows high activity against tumor cells and, at the same time, it is not toxic to primary cells.
Review
Metadata
License
This item has been published with the following license: In Copyright